World Investment Advisors Boosts Holdings in DexCom, Inc. (NASDAQ:DXCM)

World Investment Advisors raised its position in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 12.3% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 38,174 shares of the medical device company's stock after acquiring an additional 4,181 shares during the period. World Investment Advisors' holdings in DexCom were worth $2,607,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of the company. Larson Financial Group LLC lifted its stake in shares of DexCom by 40.5% during the fourth quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock worth $37,000 after buying an additional 137 shares during the period. Nia Impact Advisors LLC lifted its position in DexCom by 1.4% during the fourth quarter. Nia Impact Advisors LLC now owns 9,850 shares of the medical device company's stock valued at $766,000 after purchasing an additional 140 shares during the period. Level Four Advisory Services LLC lifted its position in DexCom by 1.1% during the fourth quarter. Level Four Advisory Services LLC now owns 13,196 shares of the medical device company's stock valued at $1,026,000 after purchasing an additional 150 shares during the period. Covestor Ltd lifted its position in DexCom by 15.6% during the fourth quarter. Covestor Ltd now owns 1,109 shares of the medical device company's stock valued at $86,000 after purchasing an additional 150 shares during the period. Finally, TD Private Client Wealth LLC lifted its position in DexCom by 62.8% during the fourth quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock valued at $34,000 after purchasing an additional 167 shares during the period. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at DexCom

In other news, EVP Michael Jon Brown sold 500 shares of the stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $82.80, for a total value of $41,400.00. Following the completion of the sale, the executive vice president owned 95,102 shares of the company's stock, valued at $7,874,445.60. This represents a 0.52% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Sadie Stern sold 1,466 shares of the stock in a transaction that occurred on Thursday, June 26th. The shares were sold at an average price of $85.06, for a total transaction of $124,697.96. Following the completion of the sale, the executive vice president directly owned 108,155 shares of the company's stock, valued at approximately $9,199,664.30. This trade represents a 1.34% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 27,190 shares of company stock worth $2,281,732 in the last 90 days. 0.32% of the stock is currently owned by insiders.

DexCom Price Performance

NASDAQ DXCM traded up $0.59 during trading hours on Thursday, hitting $85.46. 3,669,573 shares of the company's stock traded hands, compared to its average volume of 4,414,887. DexCom, Inc. has a 52-week low of $57.52 and a 52-week high of $117.19. The company has a market capitalization of $33.51 billion, a PE ratio of 63.78, a PEG ratio of 1.79 and a beta of 1.44. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.50 and a quick ratio of 1.32. The firm's 50-day moving average is $84.01 and its 200-day moving average is $79.93.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The medical device company reported $0.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.33 by ($0.01). DexCom had a net margin of 12.90% and a return on equity of 30.05%. The business had revenue of $1.04 billion for the quarter, compared to analysts' expectations of $1.02 billion. During the same period in the prior year, the company posted $0.32 EPS. The firm's revenue was up 12.5% on a year-over-year basis. Equities analysts forecast that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the stock. Truist Financial assumed coverage on shares of DexCom in a research report on Monday, June 16th. They set a "buy" rating and a $102.00 target price for the company. Canaccord Genuity Group boosted their target price on shares of DexCom from $103.00 to $106.00 and gave the company a "buy" rating in a research report on Friday, May 2nd. The Goldman Sachs Group assumed coverage on shares of DexCom in a research report on Friday, May 30th. They set a "buy" rating and a $104.00 target price for the company. Citigroup restated a "buy" rating and set a $102.00 target price (up from $82.00) on shares of DexCom in a research report on Thursday, May 22nd. Finally, Cfra Research upgraded shares of DexCom to a "hold" rating in a research report on Friday, March 21st. Five equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $98.50.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.